The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients: The effect of Δ9-THC on visceral sensitivity
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, not all findings are consistent. In another study, a single 8 mg oral dose of THC did not affect visceral sensitivity to distension in the rectum of patients with mixed-type IBS (IBS-M) or healthy volunteers, suggesting that the effect may depend on the specific gut region studied (colon versus rectum), the IBS subtype, baseline visceral hypersensitivity, or differences in dose and study”
From Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies (2025) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors
Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E., Geboes, K., Chamaillard, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1521 · Cited by 793
Symptoms and Visceral Perception in Patients With Pain-Predominant Irritable Bowel Syndrome
Lembo, T., Naliboff, B., Munakata, J., Fullerton, S., Saba, L., Tung, S., Schmulson, M., & Mayer, E. A. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01009.x · Cited by 202
Research works printed but not linked: 30
- Camilleri, 2001, Management of the irritable bowel syndrome, Gastroenterology, 120, 652, 10.1053/gast.2001.21908 · DOI · Paper page
- Bouin, 2002, Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds, Gastroenterology, 122, 1771, 10.1053/gast.2002.33601 · DOI · Paper page
- Mayer, 1994, Basic and clinical aspects of visceral hyperalgesia, Gastroenterology, 107, 271, 10.1016/0016-5085(94)90086-8 · DOI
- Klooker, 2007, Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome, Aliment Pharmacol Ther, 4, 605, 10.1111/j.1365-2036.2007.03398.x · DOI
- Kuiken, 2005, Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome, Aliment Pharmacol Ther, 2, 157, 10.1111/j.1365-2036.2005.02524.x · DOI
- Posserud, 2007, Altered rectal perception in irritable bowel syndrome is associated with symptom severity, Gastroenterology, 133, 1113, 10.1053/j.gastro.2007.07.024 · DOI · Paper page
- Van D, 2008, Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome, Clin Gastroenterol Hepatol, 6, 321, 10.1016/j.cgh.2007.12.005 · DOI
- Mertz, 1995, Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, 40, 10.1016/0016-5085(95)90267-8 · DOI · Paper page
- Munakata, 1997, Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome, Gastroenterology, 112, 55, 10.1016/S0016-5085(97)70219-1 · DOI
- Massa, 2006, Endocannabinoids and the gastrointestinal tract, J Endocrinol Invest, 3, 47
- Walker, 2002, Cannabinoid analgesia, Pharmacol Ther, 95, 127, 10.1016/S0163-7258(02)00252-8 · DOI · Paper page
- Rice, 2002, Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy, Prostaglandins Leukot Essent Fatty Acids, 3, 243, 10.1054/plef.2001.0362 · DOI
- Sanson, 2006, Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats, Neurogastroenterol Motil, 18, 949, 10.1111/j.1365-2982.2006.00819.x · DOI
- Kikuchi, 2008, Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity, J Pharmacol Sci, 106, 219, 10.1254/jphs.FP0071599 · DOI
- Esfandyari, 2007, Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study, Am J Physiol Gastrointest Liver Physiol, 293, G137, 10.1152/ajpgi.00565.2006 · DOI
- Beaumont, 2009, Effect of Delta-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans, Br J Pharmacol, 156, 153, 10.1111/j.1476-5381.2008.00010.x · DOI
- Jaggar, 1998, The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain, Pain, 2, 189, 10.1016/S0304-3959(98)00041-4 · DOI
- Martin, 1999, Spinal cannabinoids are anti-allodynic in rats with persistent inflammation, Pain, 82, 199, 10.1016/S0304-3959(99)00045-7 · DOI
- Bridges, 2001, The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain, Br J Pharmacol, 133, 586, 10.1038/sj.bjp.0704110 · DOI
- Fox, 2001, The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain, Pain, 2, 91, 10.1016/S0304-3959(00)00474-7 · DOI · Paper page
- Johanek, 2001, Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms, Pain, 93, 303, 10.1016/S0304-3959(01)00336-0 · DOI
- Rukwied, 2003, Cannabinoid agonists attenuate capsaicin-induced responses in human skin, Pain, 102, 283, 10.1016/S0304-3959(02)00401-3 · DOI
- Richardson, 1998, Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors, Pain, 75, 111, 10.1016/S0304-3959(97)00213-3 · DOI
- Schwetz, 2004, Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome, Aliment Pharmacol Ther, 1, 123, 10.1111/j.1365-2036.2004.01774.x · DOI
- Izzo, 2008, Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects, Gut, 57, 1140, 10.1136/gut.2008.148791 · DOI
- Bortolato, 2005, The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats, Psychopharmacology (Berl), 177, 264, 10.1007/s00213-004-1941-4 · DOI
- Chaperon, 1999, Behavioral effects of cannabinoid agents in animals, Crit Rev Neurobiol, 13, 243, 10.1615/CritRevNeurobiol.v13.i3.20 · DOI · Paper page
- Dewey, 1986, Cannabinoid pharmacology, Pharmacol Rev, 38, 151, 10.1016/S0031-6997(25)06864-4 · DOI
- Monnikes, 2001, Role of stress in functional gastrointestinal disorders evidence for stress-induced alterations in gastrointestinal motility and sensitivity, Dig Dis, 19, 201, 10.1159/000050681 · DOI · Paper page
- Posserud, 2004, Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress, Gut, 53, 1102, 10.1136/gut.2003.017962 · DOI
Cited by
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Wong, B. S., Camilleri, M., Busciglio, I., Carlson, P., Szarka, L. A., Burton, D., & Zinsmeister, A. R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.036 · Cited by 100
Spanagel, R., & Bilbao, A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108680 · Cited by 43
Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies
Abalo, R., Gallego-Barceló, P., & Gabbia, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199345 · Cited by 5
Metadata
- Authors
- Klooker, T. K., Leliefeld, K. E. M., Van Den Wijngaard, R. M., & Boeckxstaens, G. E. E.
- Venue
- Neurogastroenterology & Motility
- Publisher
- Wiley
- Published
- 2010-08-16
- Volume
- 23
- Issue
- 1
- Pages
- 30-e2
- ISSN
- 1350-1925
- Cited by
- 53
- References
- 2
- Language
- en
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1842 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.